![George A. Xixis](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Historique de carrière de George A. Xixis
Anciens postes connus de George A. Xixis
Sociétés | Poste | Début | Fin |
---|---|---|---|
AMDeC Foundation, Inc. | Corporate Officer/Principal | 30/01/2003 | 30/01/2003 |
CuraGen Corp.
![]() CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Corporate Officer/Principal | - | - |
Boston Harbor Angels, Inc.
![]() Boston Harbor Angels, Inc. Investment ManagersFinance Boston Harbor Angels Inc (Boston Harbor Angels) is a venture capital firm founded by Michael Williams in 2004. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 09/10/2009 | - |
Formation de George A. Xixis
Massachusetts Institute of Technology | Undergraduate Degree |
New York University | Graduate Degree |
Brooklyn Law School | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 7 |
Opérationnelle
Corporate Officer/Principal | 2 |
Graduate Degree | 2 |
Private Equity Investor | 1 |
Sectorielle
Finance | 3 |
Consumer Services | 3 |
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 3 |
---|---|
Boston Harbor Angels, Inc.
![]() Boston Harbor Angels, Inc. Investment ManagersFinance Boston Harbor Angels Inc (Boston Harbor Angels) is a venture capital firm founded by Michael Williams in 2004. The firm is headquartered in Boston, Massachusetts. | Finance |
AMDeC Foundation, Inc. | |
CuraGen Corp.
![]() CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Health Technology |
- Bourse
- Insiders
- George A. Xixis
- Expérience